Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • TissueGene-C: Phase II data

    Kolon Life Science Inc. (KOSDAQ:102940), Gwacheon, South Korea TissueGene Inc., Rockville, Md. Product: TissueGene-C (TG-C) Business: Autoimmune Molecular target: Transforming growth factor (TGF) beta 1 (TGFB1) …

    Published on 5/18/2015
  • TPI 287: Interim Phase I/II data

    Cortice Biosciences Inc., New York, N.Y. Product: TPI 287 Business: Cancer Molecular target: Not available Description: Microtubule stabilization agent Indication: Treat glioblastoma multiforme (GBM) Endpoint: Safety …

    Published on 5/18/2015
  • Venetoclax: Interim Phase I data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Venetoclax (ABT-199, RG7601) (formerly GDC-0199) Business: Cancer Molecular target: B cell lymphoma 2 (BCL-2) (BCL2) …

    Published on 5/18/2015
  • X-82: Preliminary Phase I data

    Xcovery Holding Co. LLC, West Palm Beach, Fla. Product: X-82 Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF); Platelet derived growth factor receptor (PDGFR) Description: Dual inhibitor …

    Published on 5/18/2015
  • Aldoxorubicin: Interim Phase Ib data

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 5/11/2015
  • Aldoxorubicin: Interim Phase Ib data

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 5/11/2015
  • APD371: Phase I data

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Product: APD371 Business: Neurology Molecular target: Cannabinoid CB2 receptor (CNR2) Description: Cannabinoid CB2 receptor (CNR2) agonist Indication: Treat …

    Published on 5/11/2015
  • AZD5363: Phase I data

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD5363 Business: Cancer Molecular target: Protein kinase B (AKT) (AKT1) (PKB) (PKBA) Description: Protein kinase B…

    Published on 5/11/2015
  • Dalvance dalbavancin: Phase III data

    Actavis plc (NYSE:ACT), Dublin, Ireland Product: Dalvance dalbavancin (Xydalba - EU) (RQ-00000002) Business: Infectious Molecular target: D-alanyl-D-alanine Description: Second-generation glycopeptide antibiotic …

    Published on 5/11/2015
  • Diclofenac: Phase IV data

    University Hospital of Bern, Bern, Switzerland Product: Diclofenac Business: Infectious Molecular target: NA Description: NSAID Indication: Treat uncomplicated urinary tract infection (UTI) Endpoint: Proportion of …

    Published on 5/11/2015
  • Diclofenac: Phase IV data

    University Hospital of Bern, Bern, Switzerland Product: Diclofenac Business: Infectious Molecular target: NA Description: NSAID Indication: Treat uncomplicated urinary tract infection (UTI) Endpoint: Proportion of …

    Published on 5/11/2015
  • Exviera dasabuvir: Preliminary Phase IIIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Exviera dasabuvir (ABT-333) Business: Infectious Molecular target: HCV NS5B polymerase Description: Non-nucleoside HCV NS5B polymerase inhibitor Indication: Treat chronic …

    Published on 5/11/2015
  • GFT505: Additional Phase IIb data

    Genfit S.A. (Euronext:GNFT), Loos, France Product: GFT505 Business: Hepatic Molecular target: Peroxisome proliferation activated receptor (PPAR) Description: Dual peroxisome proliferation activated receptor (PPAR) alpha…

    Published on 5/11/2015
  • IB-MECA: Additional Phase II/III data

    Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Product: IB-MECA (CF101) Business: Autoimmune Molecular target: Adenosine A3 receptor (ADORA3) Description: Adenosine A3 receptor (ADORA3) …

    Published on 5/11/2015
  • JCAR017: Interim Phase I/II data

    Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: JCAR017 Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing a chimeric antigen receptor (CAR) specific to the CD19 antigen …

    Published on 5/11/2015
  • Luspatercept: Preliminary Phase II data

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Luspatercept (ACE-536) Business: Hematology Molecular target: Activin receptor type 2B (ACVR2B) Description: …

    Published on 5/11/2015
  • Onapristone: Phase I data

    Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc., Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor antagonist…

    Published on 5/11/2015
  • Oral solithromycin: Additional Phase III data

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Toyama Chemical Co. Ltd., Tokyo, Japan Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: Oral solithromycin (CEM-101) (formerly OPT-1068) Business: Infectious …

    Published on 5/11/2015
  • rAAV 2/2: Phase I/II data

    University College London, London, U.K. Product: rAAV 2/2.hRPE65p.hRPE65 Business: Ophthalmic Molecular target: Retinal pigment epithelium-specific protein 65kDa (RPE65) Description: Adeno-associated virus (AAV) vector …

    Published on 5/11/2015
  • rAAV 2/2: Phase I/II data

    University College London, London, U.K. Product: rAAV 2/2.hRPE65p.hRPE65 Business: Ophthalmic Molecular target: Retinal pigment epithelium-specific protein 65kDa (RPE65) Description: Adeno-associated virus (AAV) vector …

    Published on 5/11/2015
  • rAAV2-CBSB-hRPE65: Phase I data

    University of Pennsylvania Medical Center, Philadelphia, Pa. Product: rAAV2-CBSB-hRPE65 Business: Ophthalmic Molecular target: Retinal pigment epithelium-specific protein 65kDa (RPE65) Description: Adeno-associated …

    Published on 5/11/2015
  • rAAV2-CBSB-hRPE65: Phase I data

    University of Pennsylvania Medical Center, Philadelphia, Pa. Product: rAAV2-CBSB-hRPE65 Business: Ophthalmic Molecular target: Retinal pigment epithelium-specific protein 65kDa (RPE65) Description: Adeno-associated …

    Published on 5/11/2015
  • REC 0482: Additional Phase II data

    Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec Recordati S.p.A. (Milan:REC), Milan, Italy Product: REC 0482, NX-1207 Business: Cancer Molecular target: Undisclosed Description: Undisclosed Indication: …

    Published on 5/11/2015
  • REP 2139-Ca: Interim Phase II data

    Replicor Inc., Montreal, Quebec Product: REP 2139-Ca Business: Infectious Molecular target: NA Description: Nucleic acid polymer (NAP) Indication: Treat chronic HBV and HDV co-infection Endpoint: Safety; reduction in …

    Published on 5/11/2015
  • Retinal pigment epithelial: Clinical trial data

    Ocata Therapeutics Inc. (NASDAQ:OCAT), Marlborough, Mass. Product: Retinal pigment epithelial (RPE) cell therapy Business: Ophthalmic Molecular target: Not applicable Description: Human embryonic stem cell-derived …

    Published on 5/11/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993